mRNA |
tanespimycin:gemcitabine (1:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.0085 |
0.8 |
mRNA |
CIL55A |
CTRPv2 |
pan-cancer |
AAC |
-0.012 |
0.8 |
mRNA |
TL-2-105 |
GDSC1000 |
pan-cancer |
AAC |
-0.0083 |
0.8 |
mRNA |
PHA-793887 |
CTRPv2 |
pan-cancer |
AAC |
0.008 |
0.8 |
mRNA |
Merck60 |
CTRPv2 |
pan-cancer |
AAC |
0.0076 |
0.8 |
mRNA |
BMS-536924 |
GDSC1000 |
pan-cancer |
AAC |
0.0081 |
0.8 |
mRNA |
Platin |
CTRPv2 |
pan-cancer |
AAC |
-0.0092 |
0.8 |
mRNA |
salermide:PLX-4032 (12:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.0093 |
0.8 |
mRNA |
PRL-3 Inhibitor I |
CTRPv2 |
pan-cancer |
AAC |
0.0094 |
0.8 |
mRNA |
Bortezomib |
CTRPv2 |
pan-cancer |
AAC |
0.0085 |
0.8 |